ABSTRACT
The desirable effects of most chemotherapy agents depend upon the differences in the proliferation rates between those normal cells that proliferate and the cancer cells that are the target of treatment. Since these rates may be similar, the results are unpleasant side effects that are usually dose-limiting. It is generally believed that the higher the concentration of chemotherapy the tumor can be exposed to and the longer the duration of exposure, the greater the efficacy of the treatment. The effectiveness of most antiproliferative chemotherapy is limited by the severity of these side effects. Fibrin sealant, a gel similar to a natural clot, is formed by mixing concentrates of virally-inactivated human fibrinogen and thrombin solutions. It has been used mostly as a hemostatic and/or adhesive agent in Europe and Canada for over a decade. The results indicate that fibrin sealant may be capable of serving as a delivery system for local/regional therapy of neoplasms in vivo.
